H.E.L Group signs agreement with Indian Institute of Technology (IIT) Kanpur in national initiative for sustainable energy
H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimization, safety, and scale-up, today announced it has signed an agreement with the Indian Institute of Technology Kanpur (IIT Kanpur), a prestigious Indian academic institution kickstarting scientific and technological research. The collaboration is part of a national initiative in sustainable…
Arrayjet announces collaboration with Chemspace to augment its small molecule microarray services for drug discovery
Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that it has partnered with Chemspace, the largest online catalogue of small molecules and biologics, to augment and streamline the Company’s small molecule microarray (SMM) service offering. Chemspace’s curated and deeply annotated compound libraries are now accessible through Arrayjet’s SMM CRO/CMO services for…
Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy
Grant award of £1.6M supports program of development work with Cell and Gene Therapy Catapult NK:IO’s platform, based on pioneering discoveries in NK cell biology, yields industry-leading tumour killing and cell productionMetrion Biosciences expands senior leadership team with appointments of Dr Robert Kirby as COO and Dr Edward Stevens as CSO
Dr Stevens promoted from Director of Drug Discovery, and Dr Kirby promoted from Director of Operations
FUJIFILM Irvine Scientific offers expanded capabilities of Presagen’s Life Whisperer Platform to aid with Clinical Decision-making in IVF
SANTA ANA, California - FUJIFILM Irvine Scientific, Inc., a global leader in the innovation and manufacture of cell culture solutions for the Life Science and Medical markets, announces the addition of the Life Whisperer Genetics module to its Life Whisperer software package (launched in 2021)1, enabling non-invasive evaluation of embryo genetic integrity during in vitro fertilization (IVF).
Avacta announces successful completion of fifth dose escalation in AVA6000 Phase 1 clinical study
Very positive safety profile of AVA6000 continues to be observed in the fifth cohort Several patients remain on trial in different dose cohorts and continue to receive AVA6000 as their disease has not progressedLondon and Wetherby, UK, 21
Closed Loop Medicine appoints Kate Woolland as Chief Operating Officer
Key executive appointment supports strategic operational delivery of the Company’s product and partnership programs
H.E.L Group expands into new purpose-designed facilities
· Investment in new global headquarters forms part of ongoing growth plans
Avacta appoints Shaun Chilton as Non-executive Director
Appointment brings additional, significant commercial and corporate development experience to the Board
Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations
Appointment supports growth of Metrion’s pre-clinical ion channel contract research and safety pharmacology services.
H.E.L Group expands range of BioXplorer bioreactors to support bioprocess development
Automated parallel bioreactor offering updated with increased capabilities for multi-parameter process development BioXplorer systems are modular and highly configurable with automation, process control, safety monitoring, and data recording enabled through controlAvacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce that a second milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics ("AffyXell"),
Pangaea Data awarded strategic partnership by Mersey Care NHS Foundation Trust and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC)
Pangaea Data awarded strategic partnership by Mersey Care NHS Foundation Trust and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC) to characterize patients across hard-to-diagnose mental health conditions.
Avacta acquires Coris Bioconcept, adding a broad range of marketed professional-use rapid tests to the Group
Acquisition consistent with Avacta Diagnostics M&A strategy and complements earlier acquisition of Launch Diagnostics.
Cellular Origins launches Constellation, its configurable robotic platform to enable scalable manufacture of advanced therapies
Closed, fully automated, and configurable robotic platform for cell therapy manufacture can achieve 30-fold increase in space efficiency and reduces production costs and labour by 51% and 16-fold respectively Scales cell therapy manufacturing without changing the process used inClosed Loop Medicine and Pharmanovia enter a co-development partnership for precision medicine combination therapeutics
Pharmanovia’s leading medicine brands to be combined with Closed Loop Medicine’s technology to provide dose optimized personalized therapies Global (ex-US) co-development and commercialization partnership to initially focus on next-generation drug + software productH.E.L Group makes senior appointments as it continues to scale globally
Hasan Hallaq, PhD appointed as European Sales Director, Victoria Ordsmith joins as Director of Marketing and Sarennah Longworth-Cook promoted Director of People Appointments will help drive company growth and sales of H.E.L’s laboratory systems for the pharma, bioteCellular Origins partners with ScaleReady to simplify, standardise, and automate cell therapy manufacturing
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective and efficient manufacture of cell and gene therapies (CGTs), announces collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together process development expertise, tools and technologies for scalable CGT manufacturing. The partnership aims to automate…
Global Access Diagnostics (GADx) welcomes new leadership
Global Access Diagnostics (GADx) announces today that Mr Mark Davis is stepping down as CEO and co-founder after 20 years of unwavering service, having created the organisation Mologic Ltd in June 2003 alongside his father and industry leader, Prof. Paul Davis.
Gyros Protein Technologies introduces Gyrolab Generic Cyno ADA Kit Reagents to support pre-clinical immunogenicity assessment
Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in cyno samples
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational New Drug (IND) Application in Avacta’s phase 1 multi-centre trial evaluating the safet
FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform Portfolio for Bioprocessing
Chemically defined media optimized for growth and productivity of CHO cells in perfusion and batch and fed-batch bioprocesses Manufactured to cGMP-compliant standards to support production of recombinant proteins, monoclonal antibodies, and biosimilarsAvacta opens first two US Clinical Investigator sites for AVA6000 Phase 1 clinical study
Memorial Sloan Kettering Cancer Center and Fred Hutch Cancer Center now open for patient enrolment to pre|CISION™ lead programme, AVA6000
Avacta announces first patient dosed in fifth cohort of AVA6000 Phase Ia Dose Escalation Study
Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial (ALS-6000-101) of AVA6000.